uniQure (QURE)
(Delayed Data from NSDQ)
$5.36 USD
-0.31 (-5.47%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QURE 5.36 -0.31(-5.47%)
Will QURE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QURE
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
uniQure (QURE) Soars on New Huntington's Disease Study Data
Other News for QURE
uniQure treatment of Fabry disease granted orphan designation
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure announces dosing of first patient in Phase I/IIa trial of AMT-191
Analysts Conflicted on These Healthcare Names: GoodRx Holdings (GDRX), NewAmsterdam Pharma Company (NAMS) and uniQure (QURE)
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity